Browsing Tag
ASCO 2025
7 posts
NeoGenomics launches PanTracer Tissue and HRD-enhanced profiling to accelerate ovarian cancer treatment decisions
NeoGenomics launches PanTracer Tissue and PanTracer Tissue + HRD to fast-track ovarian cancer treatment with next-gen genomic profiling and rapid HRD testing.
Johnson & Johnson’s DARZALEX FASPRO shows 95% survival at 4 years in multiple myeloma
DARZALEX FASPRO shows 95% four-year PFS and deep MRD responses in NDMM, raising its profile as a foundational frontline therapy. Read the full trial analysis.
Atezolizumab slashes colon cancer recurrence by 50% in ATOMIC trial: ASCO 2025 breakthrough
Genentech’s Tecentriq cuts recurrence risk by 50% in dMMR colon cancer, setting the stage for new adjuvant approvals after ATOMIC trial success.
ATOMIC trial breakthrough: Atezolizumab + FOLFOX cuts colon cancer recurrence risk by 50%
Atezolizumab plus FOLFOX slashes recurrence risk in stage III dMMR colon cancer, says ATOMIC trial at ASCO 2025. Is this the new standard of care?
Zai Lab and Novocure’s TTFields therapy shows survival benefit in pancreatic cancer: PANOVA-3 results unveiled at ASCO 2025
Zai Lab and Novocure report TTFields improves survival in pancreatic cancer. Read how ASCO 2025 results could reshape the standard of care.
HER3-DXd shows promise in treating brain metastases: Inside the TUXEDO-3 trial results from ASCO 2025
HER3-DXd from Daiichi Sankyo and Merck shows intracranial activity in CNS cancers, as TUXEDO-3 results presented at ASCO 2025 spark major oncology interest.
Glenmark Pharmaceuticals eyes biotech leap as ISB 2001 enters global spotlight
Glenmark Pharmaceuticals’ ISB 2001 gets FDA Fast Track for multiple myeloma. Explore how this could redefine its biotech future and rival global oncology innovators.